WuXi AppTec Co., Ltd. (WUXIF) is a publicly traded company in the Healthcare sector, operating within the Medical - Diagnostics & Research industry. The company is headquartered in Shanghai, China. The current CEO is Ge Li.
WUXIF has IPO date of 2020-03-17, 39,414 full-time employees, listed on the Other OTC, a market capitalization of $41.41B.
WuXi AppTec Co., Ltd. is a leading contract research, development, and manufacturing organization headquartered in Shanghai, China. The company provides comprehensive services across the drug development lifecycle, including discovery, preclinical testing, clinical trials, and commercial manufacturing for small molecule drugs, biologics, and cell and gene therapies. Operating through six business segments—WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and others—the company serves pharmaceutical and biotech customers globally across China, Asia, the United States, Europe, and international markets. Founded in 2000, WuXi AppTec has established itself as an integrated solution provider that supports clients from early-stage drug discovery through commercialization across multiple therapeutic modalities.
